Week in Review: 2012 China Life Science VC, M&A, and Partnering Climb
In 2012, China’s life science’s VC investment, M&A transactions, and partnering activity all rose substantially according to ChinaBio® data; Zhejiang Hisun Pharma in-licensed China rights to ThermoDox®, a liver cancer drug developed by Celsion Corporation, in a deal potentially worth hundreds of million of dollars; Simcere sold its 35% stake in Shanghai Celgen Bio-Pharmaceutical for $48.6 million; Huapont Pharma will partner with Yes Biotech, a Canadian company, to develop a new psoriasis treatment; Xceleron of the US and Crystal Pharmatech of Suzhou formed an early-stage CRO partnership; Wilex, a US diagnostics marker, engaged GeneDiagnostics to distribute its cancer biomarker test; Sihuan Pharma received SFDA approval to begin clinical trials of its innovative antibiotic; and Can-Fite Biopharma, an Israeli firm, will transfer its drug production to China. More details…. Stock Symbols: (SHA: 600267) (NSDQ: CLSN) (NYSE: SCR) (SHE: 002004) (HK: 0460) (TASE: CFBI; OTCBB: CANFY) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here